Talk to the Veterans Crisis Line now
U.S. flag
An official website of the United States government

VA Health Systems Research

Go to the VA ORD website
Go to the QUERI website

CDA 20-231 – HSR Study

CDA 20-231
Data to Clinical Action: Using Predictive Analytics to Improve Care of Veterans with Opioid Use Disorder
Corey J Hayes, PhD PharmD
Central Arkansas Veterans Healthcare System , Little Rock, AR
Little Rock, AR
Funding Period: April 2022 - March 2027


Background. Medication for opioid use disorder (MOUD) prevents overdoses and improves mortality in Veterans with OUD, but retention on MOUD is critical for achieving those clinical endpoints. Only 50% of Veterans are retained on MOUD at 6-months post-MOUD initiation. Poor engagement in additional needed care services is an important risk factor for early MOUD discontinuation. Consequently, providers’ ability to identify Veterans in need of additional care or support while on MOUD may increase the likelihood of Veterans’ continued use of MOUD. Valid predictive models can provide an accurate probability of an individual Veteran experiencing the outcome being modeled (e.g., MOUD discontinuation). Prediction of future MOUD discontinuation risk could provide an innovative and real-time method for identifying Veterans in need of additional care (e.g., peer support). Significance/Impact. Predictive models could be used to lower MOUD attrition risk and improve outcomes for this Veteran population by continuously monitoring their risk of MOUD discontinuation in real-time during active MOUD treatment and identifying those Veterans in need of additional care (e.g., if increasing risk between visits, providers might add peer support services to a treatment plan). Innovation. This CDA-2 encompasses three HSR&D research priority areas (opioid/pain, health care informatics, and access to care) while crosscutting HSR methods of “big” data and implementation science, all in an effort to improve care and outcomes for Veterans with OUD. This study will also be the first to develop and pilot test a clinical decision support tool (CDST), based on a predictive model, to improve Veterans’ MOUD retention. Specific Aims. (1) To develop and validate PREMMOUD, a PREdictive Model for MOUD discontinuation. Hypotheses: (H1) I will develop a predictive model with good discrimination (e.g., c-statistic, a measure of goodness-of-fit, ≥0.8) for identifying Veterans likely to discontinue MOUD within the initial 6 months of treatment; (H2) the model generated using neural network techniques will have better discrimination than the models generated using random forest and logistic regression techniques. (2) To adapt PREMMOUD into a CDST to continuously monitor risk of MOUD discontinuation and provide clinical guidelines for addressing the primary risk factors driving the PREMMOUD score. (3) To assess (a) the feasibility of conducting a large scale, randomized controlled trial (RCT) to test PREMMOUD CDST’s (P-CDST) effectiveness as well as (b) P- CDST’s acceptability among waivered providers. Hypotheses: (H3) The feasibility of conducting a large-scale RCT to evaluate P-CDST’s effectiveness will be supported; (H4) P-CDST will be acceptable among VHA waivered providers. Methodology. Using machine-learning methods and data from the VHA Corporate Data Warehouse (2006-2019), I will train and validate PREMMOUD in a national sample of Veterans initiating MOUD (Aim 1). For Aim 2, I will conduct two rounds of focus groups with key stakeholders (VHA providers, Veterans receiving MOUD, VHA operations partners) to inform the creation of a beta-version of P-CDST to be integrated into CPRS/Cerner. To build P-CDST, I will use VHA CDW data, PREMMOUD, SQL Server Reporting Services (SSRS) and the Business Intelligence Service Line (BISL) platform. P-CDST will contain the patient’s real-time PREMMOUD score as well as clinical guidelines to support the provider in addressing the Veteran’s specific risk factors driving the PREMMOUD score. For Aim 3, I will conduct a single-arm, two- site pilot trial to assess study feasibility (provider enrollment, frequency of P-CDST use, and follow-up rates) and P-CDST’s acceptability (clinical usability of P-CDST). Implementation/Next Steps. Aim 1 will support an HSR&D IIR submission in Year 3 to assess whether PREMMOUD can be used to identify which Veterans, receiving MOUD, can effectively be treated in specialty care versus non-specialty care and which Veterans benefit from additional supportive services. A second IIR proposal will be submitted post CDA-2 to conduct an RCT, using a hybrid design, to evaluate the effectiveness and implementation potential of P-CDST in VHA.

External Links for this Project

NIH Reporter

Grant Number: IK2HX003358-01A1

Dimensions for VA

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

Learn more about Dimensions for VA.

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.
    Search Dimensions for this project


Journal Articles

  1. J Hayes C, Bin Noor N, Raciborski RA, C Martin B, J Gordon A, J Hoggatt K, Hudson T, A Cucciare M. Development and validation of machine-learning algorithms predicting retention, overdoses, and all-cause mortality among US military veterans treated with buprenorphine for opioid use disorder. Journal of addictive diseases. 2024 Jun 30; 1-18. [view]
  2. Bogulski CA, Pro G, Acharya M, Ali MM, Brown CC, Hayes CJ, Eswaran H. The association between rurality, dual Medicare/Medicaid eligibility and chronic conditions with telehealth utilization: An analysis of 2019-2020 national Medicare claims. Journal of telemedicine and telecare. 2024 Feb 5; 1357633X241226741. [view]

DRA: Substance Use Disorders, Health Systems
DRE: TRL - Applied/Translational, Data Science, Technology Development and Assessment
Keywords: Career Development
MeSH Terms: None at this time.

Questions about the HSR website? Email the Web Team

Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.